PARP Inhibitor

PARP Inhibitors (436):

Cat. No.	상품명	효과	Purity

HY-150765

PARP1-IN-12	Inhibitor
PARP1-IN-12 is a potent PARP1 inhibitor with an IC₅₀ of 2.99 nM. PARP1-IN-12 exhibits antiproliferative activity, can induce cell apoptosis and cause cycle arrest at G2/M phase. PARP1-IN-12 also can induce DNA double strand breaks (DSBs) in BRCA-deficient cells.

HY-148302

LT-626	Inhibitor
LT-626 is a potent PARP inhibitor with an IC₅₀ of 1.60 nM. LT-626 inhibits cellular PAR synthesis with an EC₅₀ of 17.9 nM and shows enhanced cytotoxicity in colorectal cancer cells harboring MRE11 mutations. LT-626 exhibits synergistic effects with Cisplatin (HY-17394), Oxaliplatin (HY-17371), and SN-38 (HY-13704) in colorectal cancer cells. LT-626 can be used for colorectal research.

HY-167762

TNKS-2-IN-4	Inhibitor
TNKS-2-IN-4 (Compound 17) is a selective TNKS-2 inhibitor with an IC₅₀ of 19 nM. TNKS-2-IN-4 exhibits anticancer activity against colorectal cancer.

HY-129599

L-2286	Inhibitor
L-2286 is an orally active PARP-1 inhibitor. L-2286 alleviates carotid artery remodeling, oxidative stress and inflammation in spontaneously hypertensive rats, protects neurons in the dorsal hippocampus, and reduces pyramidal cell loss and gliosis without affecting blood pressure. L-2286 can be used in research related to hypertension.

HY-137770

RBN010860	Inhibitor
RBN010860 (example 150) is a potent PARP7 inhibitor with an IC₅₀ of <0.1 μM. RBN010860 can be used for the study of cancer.

HY-119992

CEP-6800	Inhibitor
CEP-6800 is an inhibitor of PARP-1 with chemopotentiating ability. CEP-6800 attenuates irinotecan (HY-16562)- and Temozolomide (HY-17364)-induced poly(ADP-ribose) accumulation in LoVo as well as HT29 xenografts. CEP-6800 can suppress Calu-6 tumor growth. CEP-6800 can be studied in anti-cancer research.

HY-RS10048

Parp1 Mouse Pre-designed siRNA Set A	Inhibitor
Parp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-168851

PARP1-IN-35	Inhibitor
PARP1-IN-35 (compound T26) is a selective, orally active, cross -the blood-brain barrierPARP1 inhibitor with IC₅₀ values of 0.2, 122 nM for PARP1, PARP2, respectively. PARP1-IN-35 shows antiproliferative activity and anticancer activity. PARP1-IN-35 has the potential for the research of breast cancer.

HY-158138

TOPOI/PARP-1-IN-1	Inhibitor
TOPOI/PARP-1-IN-1 (Compound B6) is an orally active, low cytotoxic TOPOI/PARP dual inhibitor with an IC₅₀ value of 0.09 μM for PARP1. TOPOI/PARP-1-IN-1 can effectively inhibit the proliferation and migration of cancer cells. TOPOI/PARP-1-IN-1 also causes cell cycle arrest in the G0/G1 phase and induces apoptosis. The tumor growth inhibition rate (TGI) of TOPOI/PARP-1-IN-1 in mice is 75.4%.

HY-172971

ARCher-142	Inhibitor
ARCher-142 (compound S8) is a potent tankyrase inhibitor. ARCher-142 selectively binds to ARC4 with potency of 8 µM.

HY-N0576R

Solanesol (Standard)	Inhibitor
Solanesol (Standard) is the analytical standard of Solanesol (HY-N0576). This product is intended for research and analytical applications. Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and PARP cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder.

HY-170972

PARP1/NAMPT-IN-2	Inhibitor
PARP1/NAMPT-IN-2 (Compound 13j) is a dual PARP/NAMPT inhibitor with IC₅₀ values of 0.8 nM and 18 nM for PARP1 and NAMPT, respectively. PARP1/NAMPT-IN-2 can inhibit the proliferation, migration and induce apoptosis of breast cancer cells. PARP1/NAMPT-IN-2 can be used for the research of triple-negative breast cancer.

HY-105303

CEP-9722	Inhibitor
CEP-9722, the proagent of CEP-8983, is a selective and orally active PARP-1 and PARP-2 inhibitor with IC₅₀s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects.

HY-161607

PARP7-IN-21	Inhibitor
PARP7-IN-21 (compound 128) is a potent inhibitor of PARP7, with the IC₅₀ of ＜ 10 nM.

HY-170942

CDK9/PARP-IN-1	Inhibitor
CDK9/PARP-IN-1 (compound 37) is a CDK9/PARP inhibitor. CDK9/PARP-IN-1 inhibits CDK9 and PARP1 with IC₅₀s of 118 and 107 nM, respectively. CDK9/PARP-IN-1 exhibits broad-spectrum antiproliferative effects across multiple cancer cell lines.

HY-180926

PARP10-IN-4	Inhibitor
PARP10-IN-4 (compound 12Z) is a potent PARP10 inhibitor with a pIC₅₀ of 7.95. also shows inhibitory activity against TNKS1, TNKS2, and PARP11 with pIC₅₀ values of 6.95, 7.03, and 7.01, respectively.

HY-155038

Antitumor agent-104	Inhibitor
Antitumor agent-104 (Compound 9) is an antitumor agent by inhibiting DNA damage repair in tumors. Antitumor agent-104 inhibits PARP1 enzymatic activity and the PAR protein level. Antitumor agent-104 also inhibits the expression of CDK12.

HY-149398

PARP-1/2-IN-2	Inhibitor
PARP-1/2-IN-2-IN-1 (Compound 12e) is a PARP1/2/CDK12 inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor.

HY-163461

4F-DDC	Inhibitor
4F-DDC is a novel PARP1 inhibitor with an IC₅₀ value of 82 nM. 4F-DDC induces DNA damage and activates the cGAS–STING pathway. 4F-DDC inhibits the growth of HCC-1937-derived tumor xenografts.

HY-174442

PARP1-IN-40	Inhibitor
PARP1-IN-40 is a highly selectively and orally active PARP1 inhibitor (IC₅₀: 0.19 nM for PARP1, 26 nM for PARP2). PARP1-IN-40 kills tumor cells by inhibiting PARP1, leading to accumulation of DNA damage. PARP1-IN-40 has high antitumor activity against BRCA mutant MDA-MB-436 cells. PARP1-IN-40 can be used in combination with chemotherapy for cancer-related research.

Name
이메일 *

	Sorry, but the email address you supplied was invalid.